Loading company
NovaBridge Biosciences
NBP · Nasdaq · ·
Next earnings: September 30, 2026
$1.38+0.4%Sep 29 close
- 1M
- -25.3%
- 6M
- -38.6%
- 1Y
- -63.6%
- 5Y
- -98.0%
NBP · Nasdaq · ·
Next earnings: September 30, 2026
$1.38+0.4%Sep 29 close
NovaBridge Biosciences is scheduled to report next on September 30, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending December 31, 2025, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2025 | 3 months toDec 31, 2024 | Change |
|---|---|---|---|
| Profit | -$30.8M | -$10.8M | -183.91% |
| Profit per share | -$0.30 | $2.58 | -111.61% |
| Free Cash Flow | -$14.6M | $151.7M | -109.62% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
NovaBridge Biosciences has no earnings call transcript available.
“Significant innovation exists across geographies and organizations, yet many promising therapies never reach their full potential,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Givastomig (TJ033721 / ABL111), a potential first-in-class CTIA, is a Claudin 18.2 × 4-1BB bispecific antibody. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed for potential treatment of gastric cancer, its current lead indication. Givastomig also has potential applicability across other Claudin 18.2+ gastrointestinal malignancies including biliary tract cancer and pancreatic ductal adenocarcinoma. Givastomig is being evaluated in a global, randomized Phase 2 study (NCT07432295), following positive topline results from a Phase 1b, multicenter, open-label study in first-line gastric cancer. NovaBridge expects to initiate a Phase 3 registrational study under a potential Accelerated Approval Pathway as early as year end 2026. Givastomig is being jointly developed through a global partnership with ABL Bio, Inc. (“ABL Bio”). NovaBridge is the lead party and shares worldwide rights equally with ABL Bio, excluding Greater China and South Korea.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from the 6-K NovaBridge Biosciences filed on August 20, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.